LACTOLOGY FOUNDATION

Aluminium-containing antacids are widely used for dyspepsia and reflux and, when used short term at recommended doses, are considered compatible with breastfeeding, although aluminium is a cumulative neurotoxic metal and prolonged high exposure should be avoided.

Therapeutic role of aluminium antacids

Aluminium-containing antacids (most commonly aluminium hydroxide, often combined with magnesium hydroxide) belong to the gastrointestinal drug group used to relieve heartburn, acid indigestion, bloating and epigastric pain associated with gastritis, peptic ulcer disease and gastro-oesophageal reflux. They act locally in the stomach by neutralising excess hydrochloric acid and increasing intragastric pH, which leads to rapid but short-lived symptom control.

Pharmacokinetics and systemic exposure

After oral administration, aluminium salts have very poor gastrointestinal absorption in individuals with normal renal function, so most of the ingested aluminium is excreted unchanged in the faeces. The small absorbed fraction is largely bound to plasma proteins and eliminated via the kidneys, which limits systemic accumulation in healthy adults but may become clinically relevant with chronic use, high doses, concomitant citrate or in renal impairment.

Toxicological profile of aluminium

From a toxicological perspective, aluminium is recognised as a cumulative neurotoxic metal able to induce encephalopathy and neurodevelopmental toxicity after sustained high exposure, particularly in patients with impaired renal function or in parenteral contexts. Long-term excessive intake has also been associated with hypophosphataemia, altered bone mineralisation and potential embryotoxic or fetotoxic effects in experimental and clinical settings, which underpins the current risk–benefit discussion around chronic over‑the‑counter aluminium exposure.

Aluminium antacids and lactation safety

Because aluminium and magnesium are poorly absorbed from the maternal gut, transfer into breast milk is expected to be minimal, and reviewers generally consider standard-dose antacids acceptable during breastfeeding. Clinical experience and guideline documents report no adverse effects in breastfed infants whose mothers use conventional aluminium/magnesium antacids, and both pregnancy and breastfeeding are not listed as contraindications in essential-drug monographs.

Aluminium in breast milk and infant exposure

Background aluminium is naturally present in breast milk, and measured mean concentrations are low compared with some infant formulas, which may contain higher aluminium levels depending on manufacturing and contamination. Comparative exposure assessments suggest that, in exclusively breastfed infants, systemic aluminium load from vaccines can markedly exceed that absorbed from breast milk, reinforcing that milk is usually a minor contributor while highlighting the importance of understanding cumulative early-life exposure from all sources.

Factors limiting drug entry into milk

General principles of drug transfer into human milk indicate that poor oral absorption, higher molecular weight, strong plasma protein binding and low maternal plasma levels all limit passage into milk. Aluminium hydroxide–based antacids fit this low-transfer profile, so infant exposure through breastfeeding remains very small relative to maternal intake, particularly with intermittent, short-term use at the lowest effective dose.

Clinical use and precautions in breastfeeding women

For lactating women with dyspeptic symptoms, guidelines and expert resources recommend simple antacid or alginate therapy as first-line options and consider aluminium/magnesium preparations safe when used as directed. However, prolonged high-dose antacid use, use in mothers with chronic kidney disease, or combination with citrate (which can increase aluminium absorption) requires individual risk assessment and monitoring, with preference for the shortest effective treatment duration.

Adverse effects and interactions

At therapeutic doses, aluminium hydroxide–containing antacids are generally well tolerated; when adverse reactions occur they are usually mild and include constipation, rebound hyperacidity and, with chronic excessive use, aluminium toxicity or phosphate depletion. Aluminium antacids can also reduce the intestinal absorption of concomitant oral medicines (e.g. some antibiotics, iron, and other cationic drugs), so spacing intervals between antacids and other oral medications is recommended.

Risk–benefit considerations in toxico-lactology

From a toxico‑lactological perspective, the local gastric mechanism of action, negligible systemic bioavailability, and correspondingly low milk transfer support the relative safety of aluminium antacids for short-term maternal use during lactation. Nonetheless, the recognised potential for aluminium to act as a neurotoxicant at higher systemic burdens justifies cautious prescribing, avoidance of unnecessary chronic exposure, and prioritisation of non-aluminium alternatives in women or infants with additional risk factors (e.g. preterm infants, renal dysfunction).